LCM
TXMD icon

Landscape Capital Management’s TherapeuticsMD TXMD Stock Holding History

Landscape Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-978
Closed -$259K – 758
2017
Q3 		$259K Buy
+978
New +$283K 0.03% 418
2015
Q1 		– Sell
-386
Closed -$86K – 679
2014
Q4 		$86K Buy
+386
New +$79.6K 0.04% 507

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Landscape Capital Management's TXMD Position: Q4 2017 in Review

Landscape Capital Management sold out of TherapeuticsMD (TXMD) in Q4 2017, closing a stake of 978 shares — an estimated $259K sold.

Landscape Capital Management first reported a position in TXMD in Q4 2014 and held it in 2 quarters. The position peaked at $259K in Q3 2017. 144 funds tracked by Wall St. Rank hold TXMD as of Q4 2017.

  • Landscape Capital Management reported no remaining TherapeuticsMD position as of Q4 2017 after selling out during the quarter.
  • Landscape Capital Management sold 978 TherapeuticsMD shares in Q4 2017, an estimated $259K.
  • Landscape Capital Management first reported a position in TherapeuticsMD in Q4 2014 and held it in 2 quarters.
  • Landscape Capital Management's TherapeuticsMD position peaked at $259K in Q3 2017.
  • 144 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2017.

Based on Landscape Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.